Total Payments
$15,229
2024 Payments
$127.98
Companies
40
Transactions
146
Medicare Patients
3,049
Medicare Billing
$988,276
Payment Breakdown by Category
Research$12,514 (82.2%)
Food & Beverage$2,203 (14.5%)
Consulting$500.00 (3.3%)
Other$11.20 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,514 | 15 | 82.2% |
| Food and Beverage | $2,203 | 129 | 14.5% |
| Consulting Fee | $500.00 | 1 | 3.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11.20 | 1 | 0.1% |
Payments by Type
Research
$12,514
15 transactions
General
$2,714
131 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $11,156 | 3 | $0 (2019) |
| Biogen, Inc. | $1,359 | 12 | $0 (2017) |
| US WorldMeds, LLC | $797.70 | 3 | $0 (2018) |
| ABBVIE INC. | $406.42 | 26 | $0 (2024) |
| Allergan, Inc. | $222.37 | 16 | $0 (2022) |
| GENZYME CORPORATION | $182.84 | 8 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $165.73 | 8 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $113.70 | 21 | $0 (2017) |
| EMD Serono, Inc. | $64.41 | 5 | $0 (2018) |
| Merz Pharmaceuticals, LLC | $55.87 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $127.98 | 6 | ABBVIE INC. ($55.09) |
| 2023 | $453.32 | 26 | AbbVie Inc. ($191.81) |
| 2022 | $122.89 | 6 | ABBVIE INC. ($52.00) |
| 2021 | $28.53 | 2 | AbbVie Inc. ($28.53) |
| 2020 | $44.76 | 3 | Allergan, Inc. ($44.76) |
| 2019 | $2,705 | 18 | Eli Lilly and Company ($2,431) |
| 2018 | $9,238 | 33 | Eli Lilly and Company ($8,725) |
| 2017 | $2,508 | 52 | Biogen, Inc. ($1,359) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 3 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2019 | Allergan Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: HYPERHYDROSIS | ||||||
| 09/16/2019 | Allergan Inc. | BOTOX (Drug) | Food and Beverage | In-kind items and services | $11.96 | General |
| Category: SPASTICITY | ||||||
| 08/27/2019 | Allergan Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: HYPERHYDROSIS | ||||||
| 08/22/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: CNS | ||||||
| 07/31/2019 | Allergan Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: HYPERHYDROSIS | ||||||
| 07/15/2019 | Allergan Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $10.07 | General |
| Category: HYPERHYDROSIS | ||||||
| 05/09/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Neuroscience | ||||||
| 04/19/2019 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $14.67 | General |
| Category: NEUROLOGY | ||||||
| 02/05/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 01/22/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,431.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/14/2019 | Medtronic USA, Inc. | ACTIVA (Device) | Food and Beverage | In-kind items and services | $49.67 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 12/31/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,706.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 12/13/2018 | Novartis Pharmaceuticals Corporation | AIMOVIG (Biological) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: NEUROSCIENCE | ||||||
| 11/29/2018 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Central Nervous System | ||||||
| 11/19/2018 | Novartis Pharmaceuticals Corporation | AIMOVIG (Biological) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2018 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2018 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $11.52 | General |
| Category: Immunology and Neurology | ||||||
| 10/31/2018 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Food and Beverage | Cash or cash equivalent | $20.57 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 10/25/2018 | Allergan Inc. | BOTOX - NEUROLOGY (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2018 | US WorldMeds, LLC | MYOBLOC (Biological), APOKYN, Xadago | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Neurology | ||||||
| 10/08/2018 | Impax Laboratories, Inc. | RYTARY (Drug) | Food and Beverage | In-kind items and services | $11.22 | General |
| Category: NEUROLOGY | ||||||
| 09/11/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2018 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $12.39 | General |
| Category: Neuroscience | ||||||
| 08/14/2018 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Immunology | ||||||
| 08/10/2018 | ARBOR PHARMACEUTICALS, INC. | Horizant (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Sleep | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $10,137 | 2 |
| Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biogen, Inc. | $1,359 | 12 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,019 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 718 | 26,637 | $1.0M | $370,634 |
| 2022 | 12 | 792 | 14,339 | $537,063 | $148,181 |
| 2021 | 11 | 676 | 12,929 | $481,895 | $138,863 |
| 2020 | 19 | 863 | 23,837 | $993,117 | $330,599 |
Total Patients
3,049
Total Services
77,742
Medicare Billing
$988,276
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 16 | 3,140 | $282,600 | $120,064 | 42.5% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2023 | 13 | 5,700 | $199,500 | $109,241 | 54.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 18 | 10,880 | $141,440 | $51,579 | 36.5% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 12 | 4,350 | $47,850 | $17,477 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 118 | 143 | $42,900 | $17,299 | 40.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 149 | 149 | $56,620 | $15,911 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 119 | 136 | $29,920 | $11,675 | 39.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $15,910 | $5,669 | 35.6% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 14 | 47 | $24,910 | $5,443 | 21.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 30 | 37 | $18,870 | $3,398 | 18.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 37 | 72 | $16,416 | $3,171 | 19.3% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 33 | 33 | $65,340 | $2,952 | 4.5% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 15 | 15 | $33,525 | $2,210 | 6.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 32 | $4,800 | $1,991 | 41.5% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 18 | 72 | $11,952 | $1,012 | 8.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 41 | $4,100 | $477.90 | 11.7% |
| A9585 | Injection, gadobutrol, 0.1 ml | Office | 2023 | 17 | 1,650 | $2,475 | $402.59 | 16.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 16 | 89 | $1,335 | $383.65 | 28.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 14 | $2,324 | $276.92 | 11.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 18 | 11,300 | $146,900 | $55,185 | 37.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 212 | 212 | $80,560 | $24,366 | 30.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 140 | 172 | $51,600 | $21,653 | 42.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 178 | 201 | $44,220 | $17,994 | 40.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 76 | 76 | $32,680 | $11,864 | 36.3% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 11 | 35 | $18,550 | $4,874 | 26.3% |
About Dr. Bradley Robottom, MD
Dr. Bradley Robottom, MD is a Neurology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1558486688.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bradley Robottom, MD has received a total of $15,229 in payments from pharmaceutical and medical device companies, with $127.98 received in 2024. These payments were reported across 146 transactions from 40 companies. The most common payment nature is "" ($12,514).
As a Medicare-enrolled provider, Robottom has provided services to 3,049 Medicare beneficiaries, totaling 77,742 services with total Medicare billing of $988,276. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Durham, NC
- Active Since 03/20/2007
- Last Updated 08/03/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1558486688
Products in Payments
- Xadago (Drug) $783.41
- BOTOX (Biological) $329.80
- TROKENDI XR (Drug) $113.70
- AUBAGIO (Drug) $98.55
- UBRELVY (Drug) $96.49
- LEMTRADA (Drug) $84.29
- KESIMPTA (Drug) $82.93
- Zinbryta (Biological) $78.99
- Rebif (Biological) $64.41
- Xeomin (Biological) $55.87
- ACTIVA (Device) $49.67
- Aimovig (Biological) $49.23
- Radicava (Drug) $45.92
- AIMOVIG (Biological) $44.54
- BOTOX (Drug) $44.40
- VYVGART HYTRULO (Drug) $40.54
- VYEPTI (Biological) $31.31
- AMYVID (Drug) $30.02
- APTIOM (Drug) $26.03
- COPAXONE (Drug) $25.10
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Durham
Mark Skeen, M.d, M.D
Neurology — Payments: $770,195
Neurology $770,195
Dr. Kevin Kahn, Md, MD
Neurology — Payments: $662,344
Neurology $662,344
Dr. Alan Finkel, Md, MD
Neurology — Payments: $405,703
Neurology $405,703
Natalia Gonzalez, Md, MD
Neurology — Payments: $219,812
Neurology $219,812
Dr. Anne Calhoun, Md, MD
Neurology — Payments: $203,020
Neurology $203,020
Dr. Jeffrey Guptill, M.d, M.D
Neurology — Payments: $191,526
Neurology $191,526